Anson Funds Management LP - Oct 11, 2023 Form 4 Insider Report for MEI Pharma, Inc. (MEIP)

Role
10%+ Owner
Signature
/s/ Bruce R. Winson, manager of Anson Management GP LLC, general partner of Anson Funds Management LP
Stock symbol
MEIP
Transactions as of
Oct 11, 2023
Transactions value $
$350,000
Form type
4
Date filed
10/13/2023, 05:02 PM
Previous filing
Sep 25, 2023
Next filing
Oct 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MEIP Common Stock Exercise of in-the-money or at-the-money derivative security $280K +40K +4.63% $7.00 904K Oct 11, 2023 See footnotes F1, F2, F3
transaction MEIP Common Stock Exercise of in-the-money or at-the-money derivative security $70K +10K +1.11% $7.00 914K Oct 11, 2023 See footnotes F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MEIP Put Option (obligation to buy) Exercise of in-the-money or at-the-money derivative security $0 -400 -4.44% $0.00 8.6K Oct 11, 2023 Common Stock 40K $7.00 See footnotes F1, F2, F3
transaction MEIP Put Option (obligation to buy) Exercise of in-the-money or at-the-money derivative security $0 -100 -1.16% $0.00 8.5K Oct 11, 2023 Common Stock 10K $7.00 See footnotes F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.
F2 Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
F3 Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.